U.S. Biopharmaceutical Third-party Logistics Market Size | Companies
The U.S. biopharmaceutical third-party logistics market size was exhibited at USD 48.85 billion in 2023 and is projected to hit around USD 99.75 billion by 2033, growing at a CAGR of 7.4% during the forecast period 2024 to 2033.
The U.S. biopharmaceutical third-party logistics (3PL) market represents a vital infrastructure component in the pharmaceutical supply chain, especially for high-value and sensitive biopharma products. As the industry increasingly relies on complex biological therapies including vaccines, monoclonal antibodies, and plasma-derived products specialized logistics capabilities have become indispensable. These include temperature-controlled storage, real-time tracking, compliance with FDA and DEA regulations, and timely delivery to hospitals, pharmacies, and research institutions.
The market has grown significantly with the rise in biologics, biosimilars, and specialty drugs. Furthermore, the demand for cold chain solutions has surged in the post-COVID era, emphasizing the need for robust logistics services tailored to fragile biopharmaceutical formulations. Outsourcing logistics to experienced 3PL providers has become a strategic choice for biopharma firms aiming to reduce operational complexity, ensure compliance, and focus on core R&D functions.
From just-in-time delivery systems to end-to-end supply chain visibility, third-party logistics providers are leveraging digital tools, AI, and automation to enhance service quality and reduce risk. This market continues to evolve with strong investment flows, innovation in temperature monitoring, and integration with manufacturing and distribution ecosystems.
Rising Demand for Cold Chain Logistics: The increase in temperature-sensitive drugs is driving innovations in packaging, tracking, and temperature assurance systems.
Digital Transformation and Real-Time Monitoring: IoT-enabled tracking systems are gaining prominence for ensuring shipment integrity.
Outsourcing of Supply Chain Functions: Biopharma companies are increasingly outsourcing logistics to reduce capital investment and ensure compliance.
Customized Distribution Models for Specialty Drugs: Specialty pharmacies and direct-to-patient models are reshaping last-mile delivery strategies.
Expansion of Warehousing Infrastructure: Investment in GDP-compliant warehouses, particularly near urban hubs and ports, is increasing.
Focus on Sustainability: Green logistics and sustainable packaging solutions are being integrated into biopharma supply chains.
| Report Coverage | Details |
| Market Size in 2024 | USD 52.46 Billion |
| Market Size by 2033 | USD 99.75 Billion |
| Growth Rate From 2024 to 2033 | CAGR of 7.4% |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Segments Covered | Supply Chain, Service Type, Product Type |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Key Companies Profiled | FedEx; DHL International GmbH; SF Express; United Parcel Service of America, Inc.; AmerisourceBergen Corporation; DB Schenker; KUEHNE + NAGEL; Kerry Logistics Network Ltd.; Agility |
Cold chain logistics dominated the supply chain segment in the U.S. biopharmaceutical 3PL market, primarily due to the surge in temperature-sensitive drug categories like vaccines, biosimilars, and monoclonal antibodies. These biologics require storage and transportation in refrigerated or frozen conditions, making cold chain capabilities essential. Sophisticated cold chain management systems with temperature mapping, validated containers, and real-time monitoring are increasingly demanded by pharmaceutical manufacturers.
Non-cold chain logistics, while significant, is witnessing moderate growth as traditional small-molecule drugs continue to be a part of biopharma supply chains. However, the shift in drug development toward more complex biologics is reshaping demand dynamics. Even generics and some oral drugs that don't require refrigeration are being bundled with cold chain services for consolidated delivery.
Transportation services held the largest share in the service type segment, driven by the urgent need for secure and timely delivery of biopharma products across state lines and regions. Within transportation, air freight emerged as the leading mode, offering rapid transit times for life-saving drugs and temperature-sensitive products. For example, air cargo was pivotal in distributing COVID-19 vaccines with stringent cold chain requirements.
Warehousing and storage services are the fastest-growing, supported by increased demand for regional storage hubs and temperature-controlled distribution centers. These facilities provide buffer storage for demand fluctuations and offer value-added services like packaging, inventory control, and label compliance. The rise in specialty drug launches is creating a need for more decentralized and strategically located warehouses.
Specialty drugs dominated the product type segment, reflecting their increasing share in total pharmaceutical sales. These therapies often require unique handling conditions, customized delivery models, and tighter inventory controls. The 3PL partners for specialty drugs must meet specific regulatory and patient-centric service expectations. Given their complexity and high cost, logistics precision is paramount to prevent waste or delays.
Plasma-derived products are the fastest-growing product category, driven by increasing therapeutic applications in immunology, hematology, and neurology. These products are exceptionally sensitive to environmental conditions and require constant cold chain integrity. The growing prevalence of chronic and rare diseases is fueling demand for these therapies, thereby increasing pressure on logistics firms to meet high service standards.
The U.S. stands as the world’s largest market for biopharmaceuticals, and correspondingly, its logistics infrastructure is among the most advanced. Stringent FDA regulations, combined with a culture of innovation, have pushed logistics providers to offer high-precision, tech-enabled services. Urban centers like New Jersey, California, and Texas are hubs for pharmaceutical warehousing, while air cargo networks facilitate intercontinental and intra-national biopharma movement.
The growth of patient-centric models such as direct-to-patient delivery, coupled with value-based healthcare, is reshaping expectations from logistics providers. U.S. policies promoting domestic manufacturing of critical pharmaceuticals and expanding vaccine supply chains are further intensifying the need for reliable 3PL partners. Strategic collaborations, tech integration, and infrastructure upgrades are driving continued transformation of the U.S. 3PL market.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the U.S. biopharmaceutical third-party logistics market
Supply Chain
Service Type
Product Type
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers